KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Interest Expense

Cost of servicing the company's debt during the period.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Interest Expense · Q4 FY2026 · quarter ended Dec 2025

Interest expense of $5.59M in Q4 FY2026

Q4 FY2026 interest expense was $5.59M. Trailing-twelve-month interest expense was $22.51M.

Context

  • Interest expense amounted to 26.3% of revenue in FY2026.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $5.59M or moves back toward the trailing-twelve-month quarterly average of $5.63M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$5.59M+17.4% QoQ
Last fiscal yearDec 2025
$19.34M— YoY
LTMDec 2025
$22.51M— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2026
19.34M USD
Year-over-year change
+234.4%

Interest Expense vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 interest expense of $22.51M is the 2nd highest of the 10 companies compared; the peer median is $1.33M.
  • Interest expense amounts to 19.4% of revenue for KALV, versus a peer median of 2.5%.
KALV Competitors Peer median
Interest Expense for KALV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ADCTADC Therapeutics S.A.LTM Mar 2026$51.75M +3.6%+12.0%65.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$22.51M ——19.4%
OMEROmeros CorporationLTM Mar 2026$14.64M -27.2%—147.9%
GOSSGossamer Bio, Inc.LTM Mar 2026$11M -1.2%-7.5%19.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$6.9M -12.6%+25.5%2.3%
VSTMVerastem, Inc.LTM Mar 2026$1.33M -63.4%-18.9%2.7%
BCYCBicycle Therapeutics plcLTM Mar 2026$203K -78.9%-60.5%0.3%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 ———
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
PRTAProthena Corporation plcLTM Mar 2026$0 ——0.0%
Peer median (excluding KALV) $1.33M-19.9%-7.5%2.5%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.